Studies have shown that FOXA1 expression is increased in endocrine therapy-resistant breast cancer, and FOXA1 is involved in the formation of drug resistance by regulating downstream gene expression through transcriptional reprogramming [159, 160]. Here, FOXA1 is linked to breast cancer.